top of page
To develop novel healthcare applications that harness the therapeutic properties of Nitric Oxide (NO) as an antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic agent across a targeted spectrum of medicine.
Founded in 2014, NOTA Laboratories is focused on developing NO delivery platform technologies that have broad applicability in advancing the treatment for many debilitating and potentially life-threatening conditions and diseases, including Sars CoV-2 (COVID-19), the seasonal flu, the common cold, systemic inflammatory response syndrome (SIRS), chronic rhinosinusitis (CRS), COPD, and catheter related bloodstream infection (CRBSI). NOTA has received generous funding from the US National Institutes of Health through the small business innovation program.
The NOTA Laboratories team is comprised of respected academic researchers and practicing specialized physicians. As several related NO enhancement technologies are currently in the development stage, the team is ideally comprised to prove the safety and efficacy of its
bottom of page